Novel Psychoactive Agents in the Treatment of Developmental Disorders

Sokol, Mae S.; Campbell, Magda

doi:10.1007/978-1-4613-8774-9_7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Other Agents1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1989

2000

Publication Types

Select...

Book4

Article2

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 11 publications

(2 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that naltrexone, an opioid antagonist, in doses of 50 mg-100 mg/day may be useful in treating self-injurious behavior. 82 A study on three bulimic TBI patients 83 reported its efficacy.…”

Section: Other Agentsmentioning

confidence: 99%

Neuropsychiatric Sequelae of Traumatic Brain Injury

2000

View full text Add to dashboard Cite

Section: Other Agentsmentioning

confidence: 99%

Neuropsychiatric Sequelae of Traumatic Brain Injury

2000

View full text Add to dashboard Cite

“…In most applied settings, aggression among the developmentally disabled is treated via a combination of behavior modification and pharmacotherapy (Dosen & Menolascino, 1990;Gualtieri, Golden, & Fahs, 1983;Matson & Gorman-Smith, 1986;Sokol & Campbell, 1988). Regarding behavior modification, it is recommended that operant-based behavioral programs be characterized by at least three criteria.…”

mentioning

confidence: 99%

Case study: The combined use of imipramine and behavior modification to reduce aggression in an adult male diagnosed as having autistic disorder

Hittner

1994

Behavioral Interventions

View full text Add to dashboard Cite

The present study examined the behavior decelerative effects of combined imipramine (tofranil) and behavior modification in a severely retarded, depressed autistic man. A simple interrupted time-series design was conducted and the primary data analytic techniques consisted of modified trend analyses and dependent samples t-tests. Consistent with previous theory and scant empirical research, results indicated that combined imipramine and behavior modification significantly reduced daily episodes of self-directed and other-directed aggression. Specifically, controlling for the effects of time, the combined treatment regimen led to significant reductions in both level and slope across three topographies of aggressive behavior. Limitations of the present study and recommendations for future research were discussed. It was concluded that combined imipramine and behavior modification may be an effective strategy for reducing aggression in the developmentally disabled.

show abstract